## **Theodoros Kassimatis**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5406524/publications.pdf

Version: 2024-02-01

759233 713466 38 500 12 21 citations h-index g-index papers 38 38 38 943 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial. Trials, 2017, 18, 255.	1.6	67
2	Statins and prostate cancer: Molecular and clinical aspects. European Journal of Cancer, 2011, 47, 819-830.	2.8	64
3	Anaemia, microcytosis and sirolimusis iron the missing link?. Nephrology Dialysis Transplantation, 2010, 25, 1667-1675.	0.7	44
4	A Fatal Case of Paraquat Poisoning Following Minimal Dermal Exposure. Renal Failure, 2007, 29, 375-377.	2.1	36
5	Impaired desensitization of a human polymorphic $\hat{l}\pm 2B$ -adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. Cell Communication and Signaling, 2011, 9, 5.	6.5	32
6	Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples. EBioMedicine, 2019, 41, 571-583.	6.1	28
7	Statins in chronic kidney disease and kidney transplantation. Pharmacological Research, 2014, 88, 62-73.	7.1	22
8	Ex vivo delivery of Mirococept: A dose-finding study in pig kidney after showing a low dose is insufficient to reduce delayed graft function in human kidney. American Journal of Transplantation, 2021, 21, 1012-1026.	4.7	21
9	The role of statins in chronic kidney disease (CKD): Friend or foe?. , 2009, 122, 312-323.		20
10	UK renal transplant outcomes in low and high BMI recipients: the need for a national policy. Journal of Nephrology, 2020, 33, 371-381.	2.0	19
11	Chronic Exposure of Human Glomerular Epithelial Cells to High Glucose Concentration Results in Modulation of High-Affinity Glucose Transporters Expression. Renal Failure, 2007, 29, 353-358.	2.1	17
12	Dyslipidemia, statins, and CKD patients' outcomes – review of the evidence in the post-sharp era. Journal of Nephrology, 2012, 25, 460-472.	2.0	16
13	Outcomes in Third and Fourth Kidney Transplants Based on the Type of Donor. Transplantation, 2019, 103, 1494-1503.	1.0	14
14	Transcription Factor Sp1 Expression Is Upregulated in Human Glomerulonephritis: Correlation with pSmad2/3 and p300 Expression and Renal Injury. Renal Failure, 2010, 32, 243-253.	2.1	13
15	Long-term safety and efficacy of renin–angiotensin blockade in atherosclerotic renal artery stenosis. International Urology and Nephrology, 2012, 44, 1451-1459.	1.4	9
16	Duration of delayed graft function and outcomes after kidney transplantation from controlled donation after circulatory death donors: aÂretrospective study. Transplant International, 2019, 32, 635-645.	1.6	9
17	Chronic histological changes in deceased donor kidneys at implantation do not predict graft survival: a singleâ€centre retrospective analysis. Transplant International, 2019, 32, 523-534.	1.6	9
18	COVID-19 in Kidney Transplant Patients From a Large UK Transplant Center: Exploring Risk Factors for Disease Severity. Transplantation Proceedings, 2021, 53, 1160-1168.	0.6	9

#	Article	IF	CITATIONS
19	Hypoperfusion warm ischaemia time in renal transplants from donors after circulatory death. Nephrology Dialysis Transplantation, 2020, 35, 1628-1634.	0.7	8
20	Rosuvastatin in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 361, 93-95.	27.0	6
21	The use of lepirudin in haemodialysis complicated with heparin-induced thrombocytopenia type II (HIT) Tj ETQq1	1 0.78431 0.7	.4 ggBT /Ove
22	Perioperative administration of high-dose recombinant human erythropoietin for delayed graft function prevention in kidney transplantation: a meta-analysis. Transplant International, 2015, 28, 330-340.	1.6	5
23	Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation. Renal Failure, 2014, 36, 1310-1316.	2.1	4
24	Successful medical treatment of emphysematous pyelonephritis in chronic hemodialysis. Hemodialysis International, 2015, 19, E54-8.	0.9	4
25	Individualization of theophylline infusion rate on the basis of a nonlinear compartmental pharmacokinetic model. European Journal of Drug Metabolism and Pharmacokinetics, 1997, 22, 265-276.	1.6	3
26	Images in Dialysis: Recurrent Flushing in a Hemodialysis Patient. Seminars in Dialysis, 2006, 19, 558-559.	1.3	3
27	Statins in Patients With Chronic Kidney Disease: A Double-Edged Sword?. Journal of the American College of Cardiology, 2008, 52, 1679.	2.8	2
28	Bilirubin as a predictor of albuminuria and atherosclerosis in type 2 diabetic patients: misleading data. Kidney International, 2009, 75, 862.	5.2	2
29	New Hope for Chronic Kidney Disease Patients After the JUPITER Trial. Journal of the American College of Cardiology, 2010, 56, 529.	2.8	2
30	Paricalcitol for reduction of albuminuria in diabetes. Lancet, The, 2011, 377, 635.	13.7	2
31	The implications of donor-recipient size mismatch in renal transplantation. Journal of Nephrology, 2021, 34, 2037-2051.	2.0	2
32	Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. Journal of Cellular and Molecular Medicine, 2006, 10, 838-851.	3 <b>.</b> 6	1
33	Letter to the Editor: "Acute Renal Failure and Hypercalcaemia: Sarcoidosis May Be the Culprit― Renal Failure, 2007, 29, 111-112.	2.1	1
34	Implications of the AURORA and JUPITER results. Nature Reviews Nephrology, 2010, 6, 636-637.	9.6	1
35	Images in Dialysis Series Editors: Ursula C. Brewster and Mark A. Perazella: Facial and Left Arm Swelling in a Hemodialysis Patient. Seminars in Dialysis, 2007, 20, 269-270.	1.3	0
36	Fatal arteriovenous graft infection in a diabetic haemodialysis patient. Emergency Medicine Journal, 2008, 25, 240-240.	1.0	0

#	Article	IF	CITATIONS
37	Prescription of Vitamin Supplementation May Not Always Be Harmless. Gerontology, 2008, 54, 69-70.	2.8	O
38	CVD in CKD: Focus on the Dyslipidemia Problem. , 2014, , 67-91.		0